Researchers seek more effective radiotherapy treatment for cancer

Treating Cancer Proton therapy exhibit rs

A pioneering research project which aims to develop a more effective radiotherapy treatment for thousands of cancer sufferers will feature in a major public exhibition by The Royal Society.

Professor Nigel Allinson, MBE, from the School of Computer Science, University of Lincoln, UK, will be showcasing the PRaVDA consortium's ground-breaking work into at this year's Summer Science Exhibition, which runs from 1st July to 6th July, 2014.

The exhibit, which will also be supported by The Christie NHS Foundation Trust, one of Europe's leading cancer centres, will reveal for the first time the new technology (patents pending) they are developing which will improve the range of treatment options available for cancer sufferers.

The World Health Organisation estimates there are 14 million new cancer cases each year. In the developed world, it is the second biggest killer – responsible for about one in four of all deaths.

Half of all cancer patients will receive radiotherapy as part of their curative treatment. All high-energy radiation damages a cell's DNA. Nearly all current radiotherapy uses external beams of x-rays. Protons, positively charged particles, offer a new form of radiotherapy.

PRaVDA (Proton Radiotherapy Verification and Dosimetry Applications) is a unique instrument that will let clinicians see in 3D how the protons interact with a tumour – the Holy Grail of Radiotherapy.

Proton beam therapy has the ability to deliver high doses of radiation directly to a tumour site with very little radiation being absorbed into healthy tissue.

This precision means that treatment is less likely to damage healthy tissue, vital in the treatment of tumours close to critical organs such as the brain or spinal cord. It is also particularly useful in treating cancer in children as there is less dose to healthy tissue which reduces the risk of second cancers arising later in life.

Professor Allinson said: "Bringing together clinicians, physicists, engineers and computer scientists we are developing, with support from a £1.6 million award from The Wellcome Trust, one of the most complex cameras ever envisaged – to see in detail, in 3D, how protons deposit their energy in a tumour while the patient is receiving treatment.

"We use the detectors from the heart of the Large Hadron Collider, which provided the evidence for the Higgs Boson, to track the paths of individual protons. We also use the CMOS technology from smartphone cameras to accurately determine the energy lost by the protons in our body, though there is enough silicon in our instrument to make over 22,000 iPhone cameras.

"The exhibit will show how seemingly very different scientific disciplines and the strengths of commercial silicon integrated technology can come together to provide the missing element for the full future exploitation of proton therapy for the better treatment of cancer."

The work of the PRaVDA consortium has the potential to make this revolutionary form of treatment a viable option for thousands more cancer sufferers. Radiotherapy would be shorter and more effective and there would be opportunities to combat some common cancers which have resisted conventional .

add to favorites email to friend print save as pdf

Related Stories

Explainer: What is proton therapy?

Aug 01, 2013

When you stand in the 27km-long Large Hadron Collider tunnel deep under Switzerland and France it looks as if the chain of blue magnets simply stretches off to infinity. So when people talk about putting ...

Recommended for you

Endogenous hormones improve breast cancer risk models

20 hours ago

(HealthDay)—Inclusion of endogenous hormones in prediction models improves prediction of invasive breast cancer risk in postmenopausal women, according to a study published online Aug. 18 in the Journal of ...

Novel oncogenic RET mutation found in small cell lung cancer

21 hours ago

For the first time an oncogenic somatic mutation at amino acid 918 in the RET (rearranged during transfection) protein has been identified in small cell lung cancer (SCLC) tumors and enforced expression of this mutation within ...

User comments